Genexine Bio Merges with AstraZeneca


On February 22, 2024, Genexine BioTech Group announced that the company has officially completed the previously announced merger agreement with AstraZeneca Group. Genexine Bio, AstraZeneca Treasury Limited (the parent company), and Grey Wolf Merger Sub (the merging subsidiary) have completed the merger in accordance with the terms and conditions of the relevant agreements and merger plan signed on December 23, 2023 (referred to as the "Merger Agreement").

AstraZeneca Treasury Limited is a private limited company established under the laws of England and Wales. The merging subsidiary is an exempted limited liability company registered under the laws of the Cayman Islands and is a wholly-owned subsidiary of the parent company. In this merger, the merging subsidiary merged with Genexine Bio, with Genexine Bio becoming a wholly-owned subsidiary of the parent company (the "Merger"). Following the completion of the merger, Genexine Bio is no longer a publicly traded company but a wholly-owned subsidiary of the parent company.

Related Article

Gout causes

Gout is a type of arthritis caused by the buildup of uric acid crystals in the joints. Uric acid is …

what causes kidney stones

Kidney stones, medically known as renal calculi, are solid masses formed in the kidneys from an aggr …